Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Less common—for the treatment of river blindness (onchocerciasis) only
Eye or eyelid irritation, pain, redness, or swelling
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common—for the treatment of river blindness (onchocerciasis) only
Fever, itching or skin rash
joint or muscle pain
painful and tender glands in neck, armpits, or groin
Less common—for the treatment of river blindness (onchocerciasis) only
swelling of the face, hands, arms, feet, or legs
Less common—for the treatment of strongyloidiasis only
skin rash or itching
Rare—for the treatment of river blindness (onchocerciasis) only
Lightheadedness when getting up from a lying or sitting position
Rare—for the treatment of strongyloidiasis only
Loss of appetite
shaking or trembling
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Copyright 2016 Truven Health Analytics, Inc. All Rights Reserved.
Side effects of Ivermectin in details
A side effect of any drug can be defined as the unwanted or undesired effect produced by the drug. The side effect can be major or in few medications minor that can be ignored. Side effects not only vary from drug to drug, but it also depends on the dose of the drug, the individual sensitivity of the person, brand or company which manufactures it. If side effects overweigh the actual effect of the medicine, it may be difficult to convince the patient to take the drug. Few patients get specific side effects to specific drugs; in that case, a doctor replaces the drug with another. If you feel any side effect and it troubles you, do not forget to share with your healthcare practitioner.
In four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of Ivermectin (Ivermectin), the following adverse reactions were reported as possibly, probably, or definitely related to Ivermectin (Ivermectin) :
Body as a Whole: asthenia/fatigue (0.9%), abdominal pain (0.9%)
Skin: pruritus (2.8%), rash (0.9%), and urticaria (0.9%).
In comparative trials, patients treated with Ivermectin (Ivermectin) experienced more abdominal distention and chest discomfort than patients treated with albendazole. However, Ivermectin (Ivermectin) was better tolerated than thiabendazole in comparative studies involving 37 patients treated with thiabendazole.
The Mazzotti-type and ophthalmologic reactions associated with the treatment of onchocerciasis or the disease itself would not be expected to occur in strongyloidiasis patients treated with Ivermectin (Ivermectin).
Laboratory Test Findings
In clinical trials involving 109 patients given either one or two doses of 170 to 200 mcg/kg Ivermectin (Ivermectin), the following laboratory abnormalities were seen regardless of drug relationship: elevation in ALT and/or AST (2%), decrease in leukocyte count (3%). Leukopenia and anemia were seen in one patient.
In clinical trials involving 963 adult patients treated with 100 to 200 mcg/kg Ivermectin (Ivermectin), worsening of the following Mazzotti reactions during the first 4 days post-treatment were reported: arthralgia/synovitis (9.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%).
In clinical trials, ophthalmological conditions were examined in 963 adult patients before treatment, at day 3, and months 3 and 6 after treatment with 100 to 200 mcg/kg Ivermectin (Ivermectin). Changes observed were primarily deterioration from baseline 3 days post-treatment. Most changes either returned to baseline condition or improved over baseline severity at the month 3 and 6 visits. The percentages of patients with worsening of the following conditions at day 3, month 3 and 6, respectively, were: limbitis: 5.5%, 4.8%, and 3.5% and punctate opacity: 1.8%, 1.8%, and 1.4%. The corresponding percentages for patients treated with placebo were: limbitis: 6.2%, 9.9%, and 9.4% and punctate opacity: 2.0%, 6.4%, and 7.2%.
In clinical trials involving 963 adult patients who received 100 to 200 mcg/kg Ivermectin (Ivermectin), the following clinical adverse reactions were reported as possibly, probably, or definitely related to the drug in ≥ 1% of the patients: facial edema (1.2%), peripheral edema (3.2%), orthostatic hypotension (1.1%), and tachycardia (3.5%). Drug-related headache and myalgia occurred in < 1% of patients (0.2% and 0.4%, respectively). However, these were the most common adverse experiences reported overall during these trials regardless of causality (22.3% and 19.7%, respectively).
A similar safety profile was observed in an open study in pediatric patients ages 6 to 13.
The following ophthalmological side effects do occur due to the disease itself but have also been reported after treatment with Ivermectin (Ivermectin) : abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. These have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment.
Laboratory Test Findings
In controlled clinical trials, the following laboratory adverse experiences were reported as possibly, probably, or definitely related to the drug in ≥ 1% of the patients: eosinophilia (3%) and hemoglobin increase (1%).
The following adverse reactions have been reported since the drug was registered overseas:
Hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, Stevens-Johnson syndrome, seizures, hepatitis, elevation of liver enzymes, and elevation of bilirubin.
What is the most important information I should know about Ivermectin?
Do not get Ivermectin lotion in your eyes, nose, or mouth. Do not get it in your vagina. If you get Ivermectin lotion in any of these areas, gently flush them with water.
Do not use more than the recommended dose or for longer than prescribed without checking with your doctor.
Wash all recently worn clothing and bedding in very hot water (150 degrees F) and tumble dry for 20 minutes.
Do not share combs, brushes, hats, or any other hair-related personal items with anyone else.
Ivermectin lotion may cause harm if it is swallowed. If you may have taken it by mouth, contact your poison control center or emergency room right away.
Ivermectin lotion should not be used in CHILDREN younger than 6 months old; safety and effectiveness in these children have not been confirmed.
PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Ivermectin lotion while you are pregnant. It is not known if Ivermectin lotion is found in breast milk after topical use. If you are or will be breast-feeding while you use Ivermectin lotion, check with your doctor. Discuss any possible risks to your baby.
Contraindication can be described as a special circumstance or a disease or a condition wherein you are not supposed to use the drug or undergo particular treatment as it can harm the patient; at times, it can be dangerous and life threatening as well. When a procedure should not be combined with other procedure or when a medicine cannot be taken with another medicine, it is called Relative contraindication. Contraindications should be taken seriously as they are based on the relative clinical experience of health care providers or from proven research findings.
Before taking Ivermectin, tell your doctor about any other medical conditions that you have, especially liver disease. If you have liver problems, you may not be able to use Ivermectin, or you may need a dosage adjustment or special tests during treatment.
Treatment with Ivermectin usually involves taking a single dose, which should be taken on an empty stomach with a full glass of water.
To be sure this medication is helping your condition, a sample of your stool (bowel movement) will need to be checked on a regular basis. It is important that you not miss any scheduled visits to your doctor.
Avoid drinking alcohol, which can increase some of the side effects of Ivermectin.
You may need to be retreated with Ivermectin several months to a year after your single dose.
Call your doctor at once if you have any problems with your eyes or your vision.
The results of a survey conducted on ndrugs.com for Ivermectin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ivermectin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported side effects
No survey data has been collected yet
There are no reviews yet. Be the first to write one!